Central Precocious Puberty

·MeSH: Puberty, Precocious

Prevalence

5.0 / 100K

4 drugs in development·4 companies·1 clinical trial

Drug Pipeline by Phase

Approved(2)

Drug	Company
fensolvi kit	Olema Pharmaceuticals, Inc. (OLMA)
supprelin la	Endo LP (NDOI)

Phase 4(2)

Drug	Company
leuprorelin acetate depot 3m	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
leuprorelin acetate depot 3m	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)

BioSniper tracks 4 drugs in development for Central Precocious Puberty across 4 companies.

There are 1 clinical trial targeting Central Precocious Puberty tracked by BioSniper.

The estimated prevalence of Central Precocious Puberty is approximately 5.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.